Abstract: Acute T lymphoblastic leukemia(T-ALL)is a highly invasive and heterogeneous hematological malignancy derived from thymic T cell progenitor cells.T-ALL accounts for approximately 15% of childhood acute lymphoblastic leukemia(ALL)and approximately 25% of adult ALL.The use of intensive chemotherapy regimens has significantly improved the prognosis of children with T-ALL,but the prognosis of adult and relapsed T-ALL patients remains poor.The development of novel targeted drugs specifically blocking T-ALL cell survival and drug-related abnormal activation signaling pathways has been considered as a new strategy for the treatment of adult and relapsed refractory T-ALL patients in recent years.The phosphatidylinositol 3-kinase(PI3K)/AKT/mammalian target of rapamycin(mTOR)pathway is a representative of the abnormal activation signaling pathways in T-ALL cells.A variety of small molecule inhibitors targeting this pathway has been successfully developed and has achieved good results in the treatment of T-ALL.PI3K/AKT/mTOR pathway-related inhibitors have higher specificity and lower toxicity than traditional chemotherapeutic drugs,and many studies have shown that they can exert synergistic effects with low-dose chemotherapeutic drugs or other targeted drugs in the treatment of T-ALL.This review will summarize recent research results in the field of PI3K/AKT/mTOR pathway and T-ALL,and elaborate the research progress of T-ALL based on targeting this pathway.

Key words: T-ALL, PI3K/AKT/mTOR, Targeted therapy, Drug resistance